6 / 34
CheckMate 057 -
Nivolumab
6
Nivo
Doc
100
90
80
70
60
50
40
30
10
0
20
Time (months)
24
21
18
15
12
9
6
3
0
27
Median
OS(mo)
Nivo
10.4
Doc
10.1
Median OS
(mo)
Nivo
17.2
Doc
9.0
≥1% PD-L1 expression level
HR (95% CI)=0.59 (0.43, 0.82)
<1% PD-L1 expression level
OS (%)
HR (95% CI)=0.90 (0.66, 1.24)
OS (%)
24
21
18
15
12
9
6
3
0
27
100
90
80
70
60
50
40
30
10
0
20
Nivo
Doc
a
PD-L1 expression was measured in pretreatment tumor biopsies (DAKO automated IHC assay).
2
CI=confidence interval; Doc=docetaxel; IHC=immunohistochemistry; Nivo=nivolumab;
1. Paz-Ares L, et al. Presented at ASCO 2015, Abstract LBA109. 2. Rizvi NA, et al.
Lancet Oncol
2015;16:257–265.
PD-L1
expression level
Median OS (mo)
HR
Nivolumab Docetaxel
≥5%
<5%
18.2
9.7
8.1
10.1
HR (95% CI) = 0.43 (0.30, 0.63)
HR (95% CI) = 1.01 (0.77, 1.34)
≥10%
<10%
19.4
9.9
8.0
10.3
HR (95% CI) = 0.40 (0.26, 0.59)
HR (95% CI) = 1.00 (0.76, 1.31)